Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI software sharpen Alzheimer's diagnosis?

NCT ID NCT07417540

Diagnosis Sponsor: NEUROPHET Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a computer program called SCALE PET helps doctors more accurately spot signs of Alzheimer's disease in brain scans. Researchers looked at 190 past scans from people with Alzheimer's or mild memory problems. Four doctors read the scans twice—once with the software and once without—to see if the software improved their ability to detect disease-related changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

190 people

The number who actually took part.

Started

Jun 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Medical imaging datasets meeting all of the following criteria will be eligible for inclusion in this study. 1. Age ≥ 50 years at the time of brain magnetic resonance imaging (MRI) 2. Participants who underwent amyloid brain PET imaging using one of the following tracers: 18F-Florbetaben, 18F-Florbetapir, 18F-Flutemetamol 3. Availability of 3D T1-weighted brain MRI. 4. The interval between amyloid PET and 3D T1-weighted MRI is within 1 year. 5. Participants meeting one of the following predefined groups based on prior visual interpretation of amyloid PET: * Aβ-positive group: Prior clinical interpretation of amyloid PET reported as Aβ positive. * Aβ-negative group: Prior clinical interpretation of amyloid PET reported as Aβ negative. Exclusion Criteria: Medical imaging datasets meeting any of the following criteria will be excluded from the study. 1. Poor image quality due to artifacts, motion, shading, or other technical issues that make visual interpretation difficult or prevent proper software processing. 2. Presence of prior brain surgery resulting in significant structural changes, or presence of intracranial metallic implants. 3. Contrast-enhanced 3D T1-weighted brain MRI. 4. Presence of structural brain lesions other than cerebral infarction. 5. Cases deemed inappropriate for study participation at the investigator's discretion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease(AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease(AD) Mild cognitive impairment (MCI)

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.